8 - 14 July 2017
These are links to news stories from the last week that may be of interest to people in the UK. The link beneath each item will take you to the original story.
Please note that the MS Trust did not write the original items and does not endorse their content nor any claims made in them.
To keep up to date on all the latest news, views and research on multiple sclerosis, sign up for Open Door, our free newsletter or regular email alerts
EMA restricts use of Zinbryta
The European Medicines Agency's Pharmacovigilance Risk Assessment Committee (PRAC) has provisionally restricted use of Zinbryta (daclizumab) to people with highly active relapsing remitting MS. This corresponds with the NICE/SMC approved use in the UK. The decision follows one death from liver failure and four other cases of severe liver injury in people taking Zinbryta.
MS Trust link: Zinbryta (daclizumab)
Breastfeeding, menstruation and risk of MS
A study found that women who had breastfed for 15 months or more were almost half as likely to develop MS as those who had breastfed for four months or fewer. Similarly, women who periods started when they were 15 or older has a lower MS risk than those who had been 11 or younger